(Q34950625)

5 August 2017

1 reference

title

HIV-1 infection in injection drug users (English)

1 reference

5 August 2017

Jonathan Allen Cohn

1

1 reference

5 August 2017

publication date

1 September 2002

1 reference

Infectious Disease Clinics of North America

5 August 2017

published in

1 reference

5 August 2017

volume

16

1 reference

5 August 2017

issue

3

1 reference

5 August 2017

page(s)

745-770

1 reference

Medical care for injection-drug users with human immunodeficiency virus infection

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

HIV incidence among injection drug users in New York City, 1992-1997: evidence for a declining epidemic

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

A multicentre study on the causes of death among Italian injecting drug users. AIDS has overtaken overdose as the principal cause of death

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Survival of HIV-1 in syringes

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

HIV-1 RNA load in needles/syringes from shooting galleries in Miami: a preliminary laboratory report

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Sex differences in risk factors for hiv seroconversion among injection drug users: a 10-year perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Sexual transmission of HIV-1 among injection drug users in San Francisco, USA: risk-factor analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

The Serostatus Approach to Fighting the HIV Epidemic: prevention strategies for infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Dynamics of behavioral risk factors for HIV/AIDS: a 6-year prospective study of injection drug users

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

The protective effect of AIDS-related behavioral change among injection drug users: a cross-national study. WHO Multi-Centre Study of AIDS and Injecting Drug Use

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Longitudinal changes in sexual risk behavior among HIV+ and HIV- male injecting drug users

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

HIV infection among patients in U.S. acute care hospitals. Strategies for the counseling and testing of the hospital patients. The Hospital HIV Surveillance Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Feasibility of an Emergency Department–Based, Risk-Targeted Voluntary HIV Screening Program

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Field evaluation of rapid HIV serologic tests for screening and confirming HIV-1 infection in Honduras

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Effectiveness of psychosocial interventions in preventing HIV risk behaviour in injecting drug users

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Maintenance of HIV risk reduction among injection opioid users: a 12 month posttreatment follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

HIV transmission and the cost-effectiveness of methadone maintenance.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

The effect of syringe exchange use on high-risk injection drug users: a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

HIV incidence among injecting drug users in New York City syringe-exchange programmes

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Prevention of HIV infection in street-recruited injection drug users. The Collaborative Injection Drug User Study (CIDUS).

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Needle-exchange attendance and health care utilization promote entry into detoxification

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Do needle exchange programmes increase the spread of HIV among injection drug users?: an investigation of the Vancouver outbreak.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

High rates of HIV infection among injection drug users participating in needle exchange programs in Montreal: results of a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Pharmacists' attitudes about pharmacy sale of needles/syringes and needle exchange programs in a city without needle/syringe prescription laws

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Community support for needle exchange programs and pharmacy sale of syringes: a household survey in Baltimore, Maryland.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Physician prescribing of sterile injection equipment to prevent HIV infection: time for action

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Syringe prescription to prevent HIV infection in Rhode Island: a case study

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Opiates as potential cofactors in progression of HIV-1 infections to AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Infection with dual-tropic human immunodeficiency virus type 1 variants associated with rapid total T cell decline and disease progression in injection drug users

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Lower prevalence and incidence of HIV-1 syncytium-inducing phenotype among injecting drug users compared with homosexual men

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Prevalence of primary HIV drug resistance among seroconverters during an explosive outbreak of HIV infection among injecting drug users

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

The effect of drug-injection behavior on genetic evolution of HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

No evidence for an effect of the CCR5 delta32/+ and CCR2b 64I/+ mutations on human immunodeficiency virus (HIV)-1 disease progression among HIV-1-infected injecting drug users

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Mutational analysis of the CCR5 and CXCR4 genes (HIV-1 co-receptors) in resistance to HIV-1 infection and AIDS development among intravenous drug users

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Human immunodeficiency virus type 1 (HIV-1)-seronegative injection drug users at risk for HIV exposure have antibodies to HLA class I antigens and T cells specific for HIV envelope

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

The incubation period to AIDS in injecting drug users estimated from prevalent cohort data, accounting for death prior to an AIDS diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Pre-AIDS mortality from natural causes associated with HIV disease progression: evidence from the European Seroconverter Study among injecting drug users

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Longitudinal human immunodeficiency virus type 1 load in the italian seroconversion study: correlates and temporal trends of virus load

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Cell-associated infectious HIV-1 viral load as a predictor of clinical progression and survival among HIV-1 infected injection drug users and homosexual men

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users: plasma viral load and CD4+ cell count

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

The influence of drug use patterns on the rate of CD4+ lymphocyte decline among HIV-1-infected injecting drug users

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

New evidence to reconcile in vitro and epidemiologic data on the possible role of heroin on CD4+ decline among HIV-infected injecting drug users

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Frequent injecting impairs lymphocyte reactivity in HIV-positive and HIV-negative drug users

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Trends in AIDS-related opportunistic infections among men who have sex with men and among injecting drug users, 1991-1996.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Coinfection and superinfection of hepatitis B virus in patients infected with human immunodeficiency virus: no evidence of faster progression to AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

High frequency of HCV infection in individuals with isolated antibody to hepatitis B core antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Serological pattern ?anti-HBc alone?: Report on a workshop

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Long-term effects of interferon-alpha in five HIV-positive patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Lamivudine as initial treatment for chronic hepatitis B in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Reactivation of hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Contrasting prevalence of delta hepatitis markers in parenteral drug abusers with and without AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Chronic delta hepatitis: is the prognosis worse when associated with hepatitis C virus and human immunodeficiency virus infections?

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Lamivudine for chronic delta hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Treatment of chronic hepatitis D with interferon alpha-2b in patients with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Interferon plus ribavirin for chronic hepatitis C in HIV-infected patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Chronic hepatitis C in HIV infection: feasibility and sustained efficacy of therapy with interferon alfa-2b and tribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus-infected patients with congenital coagulation disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Infection with GB virus C and reduced mortality among HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Effect of coinfection with GB virus C on survival among patients with HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Cause-specific mortality associated with HIV and HTLV-II infections among injecting drug users in the USA.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Bacterial pneumonia in persons infected with the human immunodeficiency virus. Pulmonary Complications of HIV Infection Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

HIV-associated dementia: new insights into disease pathogenesis and therapeutic interventions

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

HIV encephalitis, proviral load and dementia in drug users and homosexuals with AIDS. Effect of neocortical involvement

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Variable progression of HIV-associated dementia

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

The Edinburgh cohort of HIV-positive drug users: pattern of cognitive impairment in relation to progression of disease

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

The Edinburgh cohort of HIV-positive injecting drug users at 10 years after infection: a case-control study of the evolution of dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

HIV infection and cognition in intravenous drug users: long-term follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Early neuropsychological impairment in HIV-seropositive intravenous drug users: evidence from the Italian Multicentre Neuropsychological HIV Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Management of psychiatric disorders in patients infected with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Adherence to protease inhibitor therapy and outcomes in patients with HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Strategies for optimizing adherence to highly active antiretroviral therapy: lessons from research and clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Factors associated with the response to antiretroviral therapy among HIV-infected patients with and without a history of injection drug use

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Access to antiretroviral therapy in HIV-infected injection drug users

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Long-term outcomes of protease inhibitor-based therapy in antiretroviral treatment-naive HIV-infected injection drug users on methadone maintenance programmes

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

Access to medical care and service utilization among injection drug users with HIV/AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900012-0

7 January 2021

10.1016/S0891-5520(02)00012-0

Identifiers

DOI

1 reference

5 August 2017

1 reference